Active Funded Projects

Updated July 7, 2021
Data provided by University at Buffalo Sponsored Projects Services
Additional information on each funded project is also included where possible

Award Principal InvestigatorAward NameAward TypeSponsor NameAward Start DateAward End DateTotal Cost
Balthasar, Dr. JosephCatch and Release Immunotoxins: CAR-Bombs for CancerFederalNational Cancer Institute07-Dec-201630-Nov-20211,816,235.00
Balthasar, Dr. JosephCenter for Protein TherapeuticsNonfederalMultiple Sponsors01-Sep-201731-Aug-20226,524,501.70
Balthasar, Dr. JosephPharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumorsFederalNational Cancer Institute01-Jun-202031-May-20251,814,481.00
Balthasar, Dr. JosephEnhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimizationFederalNational Cancer Institute01-Jun-202131-May-20261,824,363.00
Balu-Iyer, Dr. Sathy VTolerance Inducing Phosphatidylserine (TIPS): a nanoparticle-based platform for immunotherapyNonfederalEmpire Discovery Institute13-May-202113-May-2022102,480.00
Bednarczyk, Dr. Edward MC19: Chronic Disease Medication Utilization and the Novel Coronavirus Disease 2019 (COVID-19) InfectionNonfederalAmerican College of Clinical Pharmacy01-Jan-202131-Dec-2021600.00
Bednarczyk, Dr. Edward MNYS Prescription Monitoring CE ProgramFederal Flow ThroughIsland Peer Review Organization01-Sep-202131-Oct-202212,632.00
Bies, Dr. Robert R.Physiologically-based model of the female reproductive tract: vaginal and intrauterine delivery components- Support New Approaches to Improve Product Manufacturing and QualityFederalUS Food and Drug Administration26-Sep-201825-Jan-2024888,097.00
Bies, Dr. Robert R.Film Antiretroviral Microbicide EvaluationFederal Flow ThroughMagee-Womens Research Institute and Foundation01-Jun-201931-Aug-2021195,814.00
Bies, Dr. Robert R.Pharmacokinetics of sedatives - Understanding a modifiable risk factor for pediatric deliriumFederal Flow ThroughChildrens Research Institute01-Sep-201931-Jul-202430,566.00
Bies, Dr. Robert R.Long Acting Film Technology for Contraception and HIV Prevention (LATCH)Federal Flow ThroughMagee-Womens Research Institute and Foundation01-Feb-202131-Jan-202240,060.00
Bies, Dr. Robert R.Evaluation of safety and pharmacokinetics of naltrexone implantFederal Flow ThroughResearch Foundation for Mental Hygiene01-Mar-202128-Feb-202270,875.00
Blanco, Dr. JavierDefining the Contribution of Cellular Hypoxia to the Cardiotoxicity of Anticancer Anthracyclines and TrastuzumabFederalNational Institute of General Medical Sciences01-Sep-201931-Aug-2021248,247.46
Blanco, Dr. JavierUnderstanding the Molecular Underpinnings of Anthracycline-related Cardiomyopathy in Childhood Cancer SurvivorsNonfederalBoard of Trustees of the University of Alabama Birmingham01-Feb-201931-Jan-202254,369.00
Blanco, Dr. JavierEvaluation of myocardial targets to prevent anthracycline cardiotoxicity in children with Down Syndrome and LeukemiaFederalNational Cancer Institute23-Sep-201931-Aug-2021438,625.00
Blanco, Dr. JavierThe Who and Why of Anthracycline-related Cardiotoxicity in Childhood Cancer SurvivorsNonfederalBoard of Trustees of the University of Alabama Birmingham01-Jul-201930-Jun-202237,238.00
Holsen, Dr. Maya RachaelComparison of Triple Theraply with Apixaban vs. RivaroxabanNonfederalAmerican College of Clinical Pharmacy01-Jul-202031-Dec-20214,000.00
Jacobs, Dr. David MatthewImpact of an Integrated Pharmacist and Primary Care Collaborative Transitions of Care Program on Clinical and economic Outcomes among High Risk PatientsNonfederalASHP Research and Education Foundation01-Jul-201930-Jun-202275,000.00
Jacobs, Dr. David MatthewImpact and feasibility of establishing a Community Health Worker Program within Community Pharmacy SettingsNonfederalCommunity Pharmacy Foundation01-Jan-202001-Oct-202139,533.00
Jacobs, Dr. David MatthewA qualitative study to understand patient and social factors related to nebulizer use at the transition of care in COPDNonfederalMylan Incorporated15-Nov-201901-Oct-202138,682.00
Jacobs, Dr. David MatthewIntegrative Informatics Approach to Predict Readmissions and Improve Outcomes in COPDFederalNational Heart Lung and Blood Institute01-Apr-202131-Mar-2026962,055.00
Jusko, Dr. William JMechanistic Pharmacokinetics and PharmacodynamicsFederalNational Institute of General Medical Sciences01-May-201930-Apr-20242,891,677.00
Jusko, Dr. William JTraining Program in Pharmacokinetics and PharmacodynamicsNonfederalGlaxoSmithKline03-Feb-202102-Feb-2023255,200.00
Krzyzanski, Dr. WojciechPopulation PK Model of Indomethaicin in Preterm InfantsNonfederalChildrens Mercy Hospital14-Nov-201913-Nov-202110,000.00
Ma, Dr. QingAging, Polypharmacy and Neurotoxicity in Adults Living with HIVFederalNational Institute on Aging01-May-202028-Feb-20254,006,139.00
Ma, Dr. QingBictegravir in the Elderly Living with HIV: Impact of Polypharmacy and MultimorbidityNonfederalGilead Sciences Incorporated01-Oct-201929-Sep-202267,270.00
Mager, Dr. Donald EImmunologic and Neurodevelopmental Consequences of Neonatal Anemia and Thrombocytopenia and their TreatmentsFederal Flow ThroughChildrens Hospital of Boston01-Sep-201830-Jun-2023655,055.00
Mager, Dr. Donald EOptimizing GVHD Prevention with Systems Pharmacology ModelsFederal Flow ThroughBeckman Research Institute of the City of Hope01-Jun-201931-May-2024551,996.00
Mager, Dr. Donald EMechanistic PKPD modelling of biologic treatments in lymphoid leukemia for better understanding of efficacy and safetyForeignInstitut de Recherches Internationales Servier01-Aug-201931-Jul-2022227,090.00
Meaney, Dr. Calvin J.T Regulatory Cell Response to Erythropoiesis Stimulating Agents Post-Renal TransplantationNonfederalAmerican College of Clinical Pharmacy01-Nov-201831-Oct-20215,000.00
Meaney, Dr. Calvin J.Optimizing Vancomycin Use and Clinical Outcomes in Hemodialysis PatientsNonfederalAmerican College of Clinical Pharmacy01-Jan-202131-Dec-20213,000.00
Morris, Dr. Marilyn ESBIR: Development of Novel PDE4B Inhibitors to Treat Alcohol Use DisorderFederal Flow ThroughCodex BioSolutions Incorporated23-Sep-201922-Sep-202173,459.00
Morse, Dr. GeneUniversity of Rochester HIV/AIDS Clinical Trials UnitFederal Flow ThroughUniversity of Rochester01-Dec-201330-Nov-2021480,340.00
Morse, Dr. GeneClinical Pharmacology Quality AssuranceFederalNational Institute of Allergy & Infectious Disease30-May-201529-May-202210,516,782.70
Morse, Dr. GeneHIV Research Training ProgramFederalFogarty International Center01-Apr-201628-Feb-20221,884,534.00
Morse, Dr. GeneGlobal Infectious Diseases Research Training ProgramFederalFogarty International Center11-Apr-201828-Feb-20231,125,653.00
Morse, Dr. GeneACTG Precautionary and Prohibited Medications DatabaseFederal Flow ThroughRegents of the University of California Los Angeles01-Dec-202030-Nov-2021190,000.00
Morse, Dr. GeneACTG Pharmacology Specialty LaboratoryFederal Flow ThroughRegents of the University of California Los Angeles01-Dec-202030-Nov-20271,953,875.00
Morse, Dr. GeneC19: WNY COVID-19 Research CollaborativeNonfederalJohn R Oishei Foundation01-Jun-202131-Dec-202154,450.00
Qu, Dr. JunModeling Mechanisms of Adjuvanted Influenza Vaccine Induced IgG Repertoire Diversity and Heterosubtypic Immunity URF (AWD00001405)Federal Flow ThroughUniversity of Rochester01-Feb-201731-Jan-2022467,930.00
Qu, Dr. JunGMPS-GMPR axis melanoma progression and therapyFederal Flow ThroughWake Forest University Health Sciences23-Nov-201830-Apr-2023102,352.00
Qu, Dr. JunComprehensive characterization of upregulated proteases in diseased vs normal tissuesNonfederalAbbVie Incorporated19-Jun-201931-Dec-2021224,675.00
Qu, Dr. JunNovel LC-MS strategies for comprehensive investigations of Circulating Immune Complext and MHC Presenting PeptidesNonfederalGlaxoSmithKline08-Jul-201931-Aug-2021289,493.00
Qu, Dr. JunNeuroinflammation-related phosphoprotein signaling pathways as potential therapeutic targets for GWI using an established animal modelFederal Flow ThroughWest Virginia Univ. Research Corp. on behalf of West Virginia Univ.01-Feb-202031-Jan-2022103,669.00
Qu, Dr. JunThe Network Biology of Pathogen-Host Interactions Driving Exacerbation in Chronic Obstructive Pulmonary Disease (COPD)Federal Flow ThroughBuffalo Institute for Medical Research15-Sep-201914-Sep-2022335,351.00
Qu, Dr. JunHighly sensitive multiplexed targeted mass spectrometric assays of proteins/peptides of significance in obesity researchFederal Flow ThroughPacific Northwest National Laboratory19-Feb-202031-Jul-2023618,520.00
Qu, Dr. JunExtracellular Vesicle treatment and age-related neuropathology in non-human primatesFederal Flow ThroughTrustees of Boston University15-Sep-202030-Apr-2025191,400.00
Ramanathan, Dr. MuraliThe Metabolomics-Neurofilaments-Neurodegeneration Nexus in Multiple Sclerosis ProgressionFederalUS Army Medical Research Acquisition Activity01-Jul-202030-Jun-2023957,000.00
Shah, Dr. DhavalkumarDevelopment of a quantitative systems pharmacology (QSP) Model to Support Clinical Translation of adeno-associated virus (AAV) Vectorized Brain Delivery of Anti-a-Synuclein (AS) AntibodyForeignAstraZeneca UK Limited13-Jul-202026-Jul-202180,000.00
Shah, Dr. DhavalkumarC19: UB CAT: Big-Data and AI Driven De Novo Discovery of Novel Antibodies For COVID-19NonfederalManhattan BioSolutions LLC01-Jul-202130-Jun-20223,500.00
Shah, Dr. DhavalkumarPharmacological assessment of novel computationally-designed biologic agents for the treatment of immune-mediated and viral diseasesNonfederalEVQLV01-Jul-202130-Jun-202224,500.00
Straubinger, Dr. Robert MTumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancerFederalNational Cancer Institute01-Jul-201531-Aug-20212,156,820.00
Straubinger, Dr. Robert MLarge-scale proteome-wide analysis with high accuracy/precision to guide pancreatic cancer therapy developmentFederalNational Cancer Institute21-Dec-201830-Nov-2021398,683.00
Tornatore, Dr. Kathleen MAge and Race Influences on Immunosuppression after Renal TransplantFederalNational Institute on Aging15-Aug-201830-Jun-20233,507,814.00
Tsuji, Dr. Brian TNovel Strategies for Antibiotic Combinations to Combat Gram-negative SuperbugsFederalNational Institute of Allergy & Infectious Disease20-Dec-201930-Nov-20243,920,362.00
Tsuji, Dr. Brian TExploitation of multiple heteroresistance for effective antibiotic combination therapyFederal Flow ThroughEmory University01-Jul-202030-Sep-2021126,770.20
Woo, Dr. SukyungOvercoming Resistance to Anti-VEGF Therapy with Predictive ModelingNonfederalAmerican Cancer Society09-Dec-201931-Dec-2021298,793.66
Xu, Dr. YingSBIR - Phosphodiesterase-4B (PDE4B) Inhibitors for Psychiatric DiseaseFederal Flow ThroughTetra Discovery Partners20-Sep-201631-Aug-2021642,120.48
Xu, Dr. YingPreclinical Evaluation of Tetra Compounds in MiceNonfederalTetra Discovery Partners18-Jan-202131-Jan-2022188,791.00
You, Dr. Young JaeVisible Light-Controlled Combination Strategy for Treating Nonmuscle Invasive Bladder CancersFederal Flow ThroughBoard of Regents of the University of Oklahoma09-Dec-201931-Jul-2021146,711.00
You, Dr. Young JaeMechanistic studies of gamma-glutamyl transpeptidase inhibition: A novel approach to modulating serum levels of cysteineFederal Flow ThroughBoard of Regents of the University of Oklahoma01-Jan-202031-Aug-2022121,218.00